Thyrotropin receptor autoantibodies (TSHRAbs): Epitopes, origins and clinical significance

被引:28
作者
Kohn, LD
Harii, N
机构
[1] Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA
[2] Ohio Univ, Sch Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA
关键词
Graves' disease; Hashimoto's disease; primary myxedema; stimulating TSHRAbs; blocking TSHRAbs; thyrotropin binding inhibiting immunoglobulins (TBIIs);
D O I
10.1080/08916930310001604199
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epitopes for >95% stimulating thyrotropin receptor autoantibodies (TSHRAbs) causally implicated in Graves' disease (Basedow's disease or primary hyperthyroidism) have been identified on on the N-terminal portion of the TSHR extracellular domain, residues 8-165. If the stimulating TSHRAb activity is solely dependent on this region, it is termed homogeneous ; if its activity is only largely related to this region, it is termed heterogeneous . The presence of a heterogeneous stimulating TSHRAb in a patient is associated with rapid responses to propylthiouracil or methimazole and may be predictive of long term remission with these oral immunosuppressives. Epitopes for two different Graves' autoantibodies that inhibit TSH binding, TSH binding inhibition immunoglobulins or TBIIs, have also been identified on this region of the TSHR. They do not increase cAMP levels, although one may activate the inositol phosphate, Ca ++ , arachidonate release signal system. The epitope of blocking TSHRAbs with the ability to inhibit TSH binding (TBII activity), TSH activity, and stimulating TSHRAb activity, and that are causally implicated in the primary hypothyroidism of patients with idiopathic myxedema or some patients with Hashimoto's disease have, in contrast, been largely identified largely on the C-terminal portion of the TSHR extracellular domain, residues 270-395. They have been implicated as important in pregnancy where they attenuate the signs and symptoms of Graves' hyperthyroidism. The appearance of these blocking TSHRAbs during pregnancy in Graves' patients might cause overt or occult hypothyroidism, with resultant effects on fetal development and postnatal intelligence levels. The different TSHRAbs can exist in the same patient at any moment in time, potentially making disease expression a sum of their activities. Assays taking advantage of the epitope mapping findings enable us to detect individual TSHRAbs within a single patient and to better understand their clinical significance.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 49 条
[1]  
ADAMS DD, 1987, THYROID AUTOIMMUNITY, P1
[2]   CHIMERIC STUDIES OF THE EXTRACELLULAR DOMAIN OF THE RAT THYROTROPIN (TSH) RECEPTOR - AMINO-ACIDS (268-304) IN THE TSH RECEPTOR ARE INVOLVED IN LIGAND HIGH-AFFINITY BINDING, BUT NOT IN TSH RECEPTOR-SPECIFIC SIGNAL-TRANSDUCTION [J].
AKAMIZU, T ;
INOUE, D ;
KOSUGI, S ;
BAN, T ;
KOHN, LD ;
IMURA, H ;
MORI, T .
ENDOCRINE JOURNAL, 1993, 40 (03) :363-372
[3]   FURTHER-STUDIES OF AMINO-ACIDS (268-304) IN THYROTROPIN (TSH) LUTROPIN/CHORIONIC GONADOTROPIN (LH/CG) RECEPTOR CHIMERAS - CYSTEINE-301 IS IMPORTANT IN TSH BINDING AND RECEPTOR TERTIARY STRUCTURE [J].
AKAMIZU, T ;
INOUE, D ;
KOSUGI, S ;
KOHN, LD ;
MORI, T .
THYROID, 1994, 4 (01) :43-48
[4]   THYROID-STIMULATING ANTIBODIES IN SERA FROM PATIENTS WITH GRAVES-DISEASE ARE HETEROGENEOUS IN EPITOPE RECOGNITION [J].
AKAMIZU, T ;
OKUDA, J ;
UEDA, M ;
KOSUGI, S ;
UEDA, Y ;
SUGAWA, H ;
OHTA, C ;
KIHOU, Y ;
MORI, T .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (01) :62-68
[5]   LOCALIZATION AND SYNTHESIS OF THE HORMONE-BINDING REGIONS OF THE HUMAN THYROTROPIN RECEPTOR [J].
ATASSI, MZ ;
MANSHOURI, T ;
SAKATA, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (09) :3613-3617
[6]   The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim [J].
Chen, CR ;
Pichurin, P ;
Nagayama, Y ;
Latrofa, F ;
Rapoport, B ;
McLachlan, SM .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (12) :1897-1904
[7]   Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: Characteristics of epitopes for thyrotropin receptor antibodies [J].
Chung, HK ;
Kim, WB ;
Park, DJ ;
Kohn, LD ;
Tahara, K ;
Cho, BY .
THYROID, 1999, 9 (04) :393-399
[8]  
CUNDIFF JG, 2001, J CLIN ENDOCR METAB, V86, P3998
[9]   Thyroid controversy-stimulating antibodies [J].
Davies, TF ;
Roti, E ;
Braverman, LE ;
Degroot, LJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3777-3781
[10]   DUAL MECHANISM OF PERTURBATION OF THYROTROPIN-MEDIATED ACTIVATION OF THYROID-CELLS BY ANTIBODIES TO THE THYROTROPIN RECEPTOR (TSHR) AND TSHR-DERIVED PEPTIDES [J].
DESAI, RK ;
DALLAS, JS ;
GUPTA, MK ;
SEETHARAMAIAH, GS ;
FAN, JL ;
TAHARA, K ;
KOHN, LD ;
PRABHAKAR, BS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (03) :658-663